We can’t show the full text here under this license. Use the link below to read it at the source.
Semaglutide use in people with obesity and type 2 diabetes from real‐world utilization data: An analysis of the All of US Program
Semaglutide use in people with obesity and type 2 diabetes based on real-world data from the All of Us Program
AI simplified
Abstract
In a population of 3739 patients prescribed semaglutide, average decreases were observed in BMI by 1.54 kg/min, weight by 4.65 kg, and HbA1c by 0.75%.
- Patients on injectable semaglutide averaged 301.54 days on the medication, while those on oral semaglutide averaged 172.48 days.
- Approximately 20.36% of injectable users and 24.60% of oral users had no defined end date for their treatment.
- The largest reductions in BMI, weight, and HbA1c were noted in participants using the injectable formulation, likely due to higher initial values.
- Improvements in BMI, weight, and HbA1c diminished over time but remained significantly lower than baseline levels.
- Only 1.0% of patients reported newly diagnosed common adverse events associated with semaglutide.
AI simplified
Key numbers
1.54 kg/m
Average BMI Decrease
Average change in BMI from baseline for semaglutide users with obesity.
4.65 kg
Average Weight Decrease
Average weight change from baseline for semaglutide users.
0.75%
Average HbA1c Decrease
Average change in HbA1c from baseline for semaglutide users with type 2 diabetes.